ValiRx plc (AIM:VAL)
London · Delayed Price · Currency is GBP · Price in GBX 0.1550
-0.0050 (-3.13%)
Jul 6, 2026, 4:45 PM GMT
ValiRx Revenue
In the year 2025, ValiRx had annual revenue of 31.37K GBP, down -36.97%. ValiRx had revenue of 31.37K in the half year ending December 31, 2025, with 226.79% growth.
Revenue
31.37K
Revenue Growth
-36.97%
P/S Ratio
39.16
Revenue / Employee
2.24K
Employees
14
Market Cap
1.23M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37K | -18.40K | -36.97% |
| Dec 31, 2024 | 49.78K | 40.18K | 418.49% |
| Dec 31, 2023 | 9.60K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Futura Medical | 1.70M |
| Oxford BioDynamics | 1.20M |
| OptiBiotix Health | 1.17M |
| Physiomics | 1.01M |
| Genflow Biosciences | 585.61K |
| CRISM Therapeutics | 231.00K |
| BSF Enterprise | 51.07K |
| Thalia Therapeutics | 7.26K |
ValiRx News
- 8 months ago - AIM Market Roundup: Haydale Graphene, Marechale Capital, Getech - The Armchair Trader
- 1 year ago - Small Cap Stocks: Catenai, Genip, ValiRx - The Armchair Trader
- 1 year ago - Small Cap Stocks: Guardian Metal, MediaZest, Enwell - The Armchair Trader
- 1 year ago - Small Cap Stocks: Valirx, EnergyPathways, Merit Group - The Armchair Trader